Document:

Sixth Amendment to Collaborative Research

 Exhibit 10.1 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2. 

SIXTH AMENDMENT TO 
 COLLABORATIVE RESEARCH, DEVELOPMENT 
 AND LICENSE AGREEMENTS

 THIS SIXTH AMENDMENT TO COLLABORATIVE
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the “Sixth Amendment”) is entered into as of March 28, 2011 (the “Sixth Amendment
Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and
ALLERGAN SALES, LLC, a Delaware limited liability company (“Allergan”) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a
Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan. 
 RECITALS

 WHEREAS, the parties previously entered into that certain Collaborative Research, Development and
License Agreement, dated September 24, 1997 (as amended by the First Amendment, the Second Amendment and the Third Amendment described below, the “1997 Agreement”), pursuant to which the parties conducted collaborative
research regarding, among other things, receptor selective compounds with the goal of establishing drug discovery programs related to such receptor selective compounds; 
 WHEREAS, the parties previously entered into that certain Collaborative Research, Development and License Agreement, dated July 26, 1999 (the “1999
Agreement”), pursuant to which the parties conducted collaborative research regarding [...***...] muscarinic compounds for the treatment or prevention of ocular disease; 

WHEREAS, the 1997 Agreement was first amended on March 27, 2003 (the “First
Amendment”) to continue the collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered into a new Collaborative Research, Development and License Agreement (the
“2003 Agreement”) regarding ACADIA’s chemical-genomics assets; 

WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on February 28, 2006 (the
“Second Amendment”) to continue the collaboration under the 1997 Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on other receptor selective compounds included in
ACADIA’s chemical-genomics assets; 
 WHEREAS, the 1997 Agreement and the 2003
Agreement were amended on March 3, 2008 (the “Third Amendment”) to continue the collaboration under the 1997 

  

***Confidential Treatment Requested 
 1 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 240.24b-2. 
  

Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on muscarinic compounds for eye-care applications; 

WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on April 22, 2009 (the
“Fourth Amendment”) to finalize the research under the 1997 Agreement with respect to alpha adrenergic receptors, to continue to collaborate on muscarinic compounds for eye-care applications under the 2003 Agreement, and to
expand their collaboration on [...***...] muscarinic selective compounds for eye-care indications; 

WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on March 23, 2010 (the
“Fifth Amendment”) to continue to collaborate on [...***...] muscarinic selective compounds for eye-care indications and to provide for collaboration on muscarinic selective compounds for eye care indications or on
other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement; 

WHEREAS, the parties wish to continue their research collaboration on [...***...] muscarinic
selective compounds for eye-care indications on the terms set forth below; and 
 WHEREAS,
the parties may wish to collaborate on muscarinic selective compounds for eye care indications or on other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement and on the terms set forth below.

 NOW THEREFORE, in consideration of the foregoing and the covenants and premises
contained in this Sixth Amendment, the parties hereby agree as follows: 
 1.    [...***...] Expansion
Program. The parties have agreed on a pool of ten (10) compounds from ACADIA’s library of [...***...] muscarinic selective compounds from which Allergan may chose a backup compound (the “[...***...]
Expansion Program”). The current ten (10) compounds are listed on Exhibit A hereto (the “Back-up Pool”). The Research Term of the 2003 Agreement with respect to the [...***...] Expansion Program
shall be extended to cover the period beginning March 28, 2011 and ending March 27, 2012 (the “Additional Extension Period”). During the Additional Extension Period, ACADIA will provide information on compounds
included in the Back-up Pool for continued evaluation by the parties. Further, if directed by the JRC (as defined below), ACADIA shall engage in the synthesis and evaluation of additional [...***...] muscarinic selective compounds. Allergan
may remove and add compounds to the Back-up Pool from (a) ACADIA’s existing [...***...] muscarinic selective compounds (i.e., those identified prior to the Additional Extension Period), upon mutual agreement of the parties, or
(b) from new 

  

***Confidential Treatment Requested 
 2 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 240.24b-2. 
  

compounds synthesized at the direction of the JRC, so long as the total number of compounds in the Back-up Pool does not exceed ten (10) at any given time. Allergan may select one compound
from the Back-up Pool to be treated as a Collaboration Lead Compound (as defined in the 1999 Agreement and in addition to the compound based on [...***...], which has been advanced by the parties pursuant to the 1999 Agreement) pursuant to the
terms of the 1999 Agreement. Allergan shall use reasonable efforts to select a compound from the Back-up Pool to be treated as a second Collaboration Lead Compound prior to the end of the Additional Extension Period. Allergan’s right to so
select a compound shall expire at the end of the Additional Extension Period. Upon selecting a compound from the Back-up Pool to be treated as a Collaboration Lead Compound, Allergan shall be entitled to select another compound to add to the Back-up
Pool from (a) ACADIA’s existing [...***...] muscarinic selective compounds (i.e., those identified prior to the Additional Extension Period), upon mutual agreement of the parties, or (b) from compounds synthesized at the
direction of the JRC during the Additional Extension Period, so that Allergan retains ten (10) compounds within the Back-up Pool through the end of the Additional Extension Period. If Allergan selects a Back-up Pool compound to be treated as a
Collaboration Lead Compound during the Additional Extension Period, then until one year after the end of the Additional Extension Period, Allergan may exchange such Collaboration Lead Compound for a compound within the Back-up Pool, which will then
be treated as a Collaboration Lead Compound. Other than any such exchange, the Back-up Pool will not change after the end of the Additional Extension Period. Allergan shall have no rights to the compounds remaining in the Back-up Pool, or those
compounds synthesized at the direction of the JRC that are not in the Back-up Pool, on the one-year anniversary of the end of the Additional Extension Period. 
 2.    Additional Extension Program. At the direction of the JRC, ACADIA has undertaken discovery efforts to identify new compounds that meet mutually acceptable selection
criteria for muscarinic selective compounds for [...***...]. These efforts have included and, during the Additional Extension period, will include mining of ACADIA’s library of muscarinic compounds, re-screening where desired, in vitro
pharmacology/ characterization, and supporting synthesis to enable selection of potential compounds by Allergan for in vivo pharmacology and potential development (the “Additional Extension Program”). Any muscarinic selective
compounds identified pursuant to the Additional Extension Program may be designated by Allergan as a Selected Target/Chemistry (as defined in the 2003 Agreement) in accordance with Section 5.1 of the 2003 Agreement; provided that the right to
exercise the Option (as defined in the 2003 Agreement) for such Selected Target/Chemistry shall expire on March 27, 2012, notwithstanding the Option Period definition in Section 1.45 of the 2003 Agreement. 

3.    FTE Funding. Research funding during the Additional Extension Period shall be [...***...]. During the Additional
Extension Period, Allergan shall fund a 

  

***Confidential Treatment Requested 
 3 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 240.24b-2. 
  

minimum of [...***...], and up to a maximum of [...***...]. The Joint Research Committee (the “JRC”) shall determine the work to be done under the
[...***...] Expansion Program, including the appropriate number of FTEs for such level of work. During the Additional Extension Period, Allergan, with the consent of the JRC, also may elect to pursue the Additional Extension Program. If
Allergan elects to pursue the Additional Extension Program, the JRC shall determine the number of ACADIA FTEs required for such program. The allocation of FTEs between the Additional Extension Program, if any, and the [...***...] Expansion
Program shall be decided by the JRC, provided however in the event that the parties do not agree on such allocation, notwithstanding Section 15.2 of the 2003 Agreement, [...***...]. 

4.    Research Coordinators. Allergan and ACADIA shall each appoint an individual to act as the research coordinator for such
party (each, a “Research Manager”). The Research Managers shall be the primary contact for the parties regarding the activities contemplated by this Sixth Amendment and shall facilitate all such activities hereunder. The
initial Research Manager for Allergan shall be Daniel Gil and the initial Research Manager for ACADIA shall be Ethan Burstein. Each party may replace its Research Manager with another individual at any time with prior written notice to the other
party. Each Research Manager who is not otherwise a member of the JRC shall be permitted to attend meetings of the JRC. 

5.    Patent Costs. In the event that Allergan selects a Back-up Pool compound to be treated as a Collaboration Lead Compound
pursuant to Section 1 above, then Allergan shall reimburse ACADIA for [...***...] of all reasonable out of pocket legal expenses incurred by ACADIA that are associated with the filing and prosecuting of (i) all Collaboration Patents
having one or more claims covering such compound, and (ii) any ACADIA Patents having one or more claims covering such compound. (Capitalized terms used in this paragraph that are not defined have the meaning given to such terms in the 1999
Agreement). 
 6.    Bankruptcy. All rights and licenses granted under the 1997 Agreement, the 1999
Agreement, the 2003 Agreement, and any amendments to those agreements will be considered for purposes of Section 365(n) of 11 U.S.C. (the “Bankruptcy Code”) licenses of rights to “intellectual property” as
defined under Section 101(56) of the Bankruptcy Code. The parties agree that a licensee of such rights under those agreements will retain and may fully exercise all of its rights and elections under the Bankruptcy Code. In the event that a
licensor seeks or is involuntarily placed under the protection of the Bankruptcy Code, and the trustee in bankruptcy rejects any of those agreements, the licensee hereby elects, pursuant to Section 365(n), to retain all rights granted to it
under those agreements to the extent permitted by law. 
 7.    Full Force and Effect. Except as it may specifically
be amended by this Sixth Amendment, each of the 1997 Agreement, the 1999 Agreement, the 2003 Agreement, 

  

***Confidential Treatment Requested 
 4 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 240.24b-2. 
  

and any amendments to those agreements, shall remain in full force and effect. If there is any inconsistency or conflict between any provision in this Sixth Amendment and any of the foregoing
agreements, as amended to date, the provision in this Sixth Amendment shall control. 
 8.    Miscellaneous. This
Sixth Amendment may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one instrument. This Sixth Amendment shall be governed by the laws of the State of California as such laws are
applied to contracts entered into or to be performed entirely within such state. 
 IN WITNESS
WHEREOF, the parties hereto have duly executed this SIXTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND
LICENSE AGREEMENTS. 
  

													
	 ACADIA PHARMACEUTICALS INC.
	 		 	ALLERGAN SALES, LLC, a Delaware
limited liability company, a successor in
interest of	 	
	 By: 
	 	 /s/ THOMAS H. AASEN
	 		 	 VISION PHARMACEUTICALS L.P.,
	 	
	 Name: Thomas H. Aasen

Title: Executive Vice President Chief
Business Officer and Chief
Financial Officer
	 		 	 A Texas limited partnership, dba

Allergan,
	 	
	 		 	 by Allergan General, Inc.,
 its general partner
	 	
						
		 		 		 	 By:
	 	 /s/ SCOTT M. WHITCUP
	 	
		 		 		 	 Name:
	 	 Scott M. Whitcup
	 	
		 		 		 	 Title:
	 	 Chief Scientifc Officer
	 	
					
		 		 		 	 Guarantee of performance by:
	 	
		 		 		 	 ALLERGAN, INC.
	 	
						
		 		 		 	 By:
	 	 /s/ SCOTT M. WHITCUP
	 	
		 		 		 	 Name:
	 	 Scott M. Whitcup
	 	
		 		 		 	 Title:
	 	 Chief Scientifc Officer
	 	

  

***Confidential Treatment Requested 
 5 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4)

 and 240.24b-2. 
  

Exhibit A 
 List
of Compounds Currently in Back-up Pool 
 [...***...] 

  

***Confidential Treatment Requested 
 6Termination Agreement by and between Registrant

 Exhibit 10.2 
 Termination Agreement 
  

	1.	Parties 

  

	1.1	Wihlborgs Fastigheter AB (publ) (“Wihlborgs”), corporate registration number 556367-0230, Box 97, 201 20 Malmö, Sweden 

 

	1.2	Medeon Fastigheter AB (“Medeon”), corporate registration number 556034-1140, c/o Wihlborgs Fastigheter AB (publ), Box 97, 201 20 Malmö, Sweden

  

	1.3	ACADIA Pharmaceuticals Inc. (“Acadia”), 3911 Sorrento Valley Boulevard, San Diego CA 92121, USA 

 

	1.4	Nordsviten AB (“Nordsviten”), corporate registration number 556666-6805, Medeon Science Park, 205 12 Malmö, Sweden 

 

	2.	Background 

  

	2.1	On 22 April 2004 Medeon and Acadia entered into a general agreement regarding inter alia the construction of premises located at the real estate
“Forskaren 1” in Malmö (the “General Agreement”). Medeon and Nordsviten entered into a lease agreement regarding the lease of said premises (agreement no 4881-20000) with an effective commencement date of June 1, 2005
(the “Lease”). 

  

	2.2	Nordsviten has not paid rent under the Lease for the period January-March 2011. Consequently, the tenancy is forfeited and Medeon has cancelled the Lease. Nordsviten
has not recovered the tenancy. 

  

	2.3	Medeon has filed a petition for bankruptcy regarding Nordsviten with the District Court of Malmö (case number K 1159-11). Bankruptcy hearings are scheduled to be
held on 11 April 2011 with the District Court of Malmö. Wihlborgs is the parent company of Medeon and holds all outstanding shares in Medeon. 

 The parties have now agreed, as of April 8, 2011 (the “Effective Date”), as follows: 
  

	3.	Termination of Lease and General Agreement 

  

	3.1	Acadia shall pay a total amount of SEK 12,500,000 to Medeon (the “Termination Amount”). The payment of the Termination Amount shall be made as follows:

	 	a)	SEK 4,300,000 shall be paid in cash to Medeon’s bank account no
                                         
    on the Effective Date. 

  

	 	b)	SEK 8,200,000 shall be deemed paid by the transfer of 782,339 shares of Acadia common stock (the “Shares”). Acadia’s common stock is listed on The Nasdaq
Global Market. The Shares shall be issued to Medeon on the Effective Date. Acadia warrants and represents that it has the authority to issue the Shares in accordance with the terms of this Termination Agreement and that the Shares are duly
authorized and, upon issuance in accordance with the terms of this Termination Agreement, will be validly issued, fully paid and non-assessable. Acadia shall bear any costs for the issuance of the Shares to Medeon. 

 

	 	c)	Any failure by Acadia to deliver the full Termination Amount, whether by failure to deliver the cash consideration set forth in Section 3.1 or failure to deliver
the Shares in a timely fashion, shall provide Medeon the opportunity to declare this Termination Agreement null and void. 

  

	3.2	Medeon understands that the Shares will be issued pursuant to Registration Statement No. 333- 161059, which has been declared effective by the U.S. Securities and
Exchange Commission. The Shares will be issued by Acadia’s transfer agent without any restrictive legends or trading restrictions. Medeon is acquiring the Shares for its own account and is not party to any agreement or understanding with other
persons regarding the sale or distribution of the Shares. 

  

	3.3	In exchange for the releases set forth in this Termination Agreement, Nordsviten hereby transfers and assigns to Medeon, all machinery, equipment, furniture, fixtures
and other fixed assets owned by Nordsviten located on the real estate Forskaren 1 in Malmö. The title of such equipment machinery, equipment, furniture, fixtures etc is transferred to Medeon as of the Effective Date. 

 

	3.4	Nordsviten agrees to hand over and deliver to Medeon all sets of keys, information regarding security systems, drawings, manuals, etc., which are in its possession,
relating to the premises covered by the Lease. Nordsviten shall also provide reasonable assistance to Medeon in other practical matters as regards the transfer set forth in section 3.3 above and the Lease cancellation described in section 2.2.

  

	3.5	Each party shall bear their own costs incurred in connection with this matter, including but not limited to legal fees in connection thereto. 

 

	3.6	When Acadia has paid the Termination Amount to Medeon, Medeon shall withdraw its petition for bankruptcy and request that the District Court of Malmö dismisses
case number K 1159-11. 

	3.7	By this agreement the parties have finally settled any and all claims between Wihlborgs and Medeon on the one hand and Acadia and Nordsviten on the other hand. However,
until Acadia fulfills payment in accordance with section 3.1 above, Nordsviten remains liable for any obligations relating to the Lease. The parties to this Termination Agreement mutually agree to terminate the General Agreement as of the Effective
Date and, as a result of such termination, the parties hereby acknowledge and agree that, except as expressly provided for under this Termination Agreement, their respective rights and obligations under the General Agreement are hereby terminated as
of the Effective Date and that the parties shall have no further liability to each other under the General Agreement or the Lease (or with respect to the General Agreement or the Lease), except as expressly set forth in this Termination Agreement.

  

	3.8	By signing this Termination Agreement, each of Wihlborgs and Medeon, on behalf of itself and any Medeon Releasors (defined below), confirms that they do not have any
claim, for payment for whatever reason, in relation to any, present or former, employee or member of the board of Acadia or Nordsviten. In consideration for the terms set forth in this Termination Agreement, each of Medeon and Wihlborgs, on behalf
of itself and its affiliates, and the directors, officers and employees of such entities and the successors and assigns of the foregoing (the “Medeon Releasors”), hereby releases each of Acadia, Nordsviten and their affiliates and the
directors, officers and employees of such entities (the “ACADIA Releasees”) from any and all claims, actions, causes of action, liabilities, damages, and demands of any kind, whether known or unknown that the Medeon Releasors had, has, may
have or ever claim to have against ACADIA Releasees among, under or directly or indirectly related to the General Agreement, the Lease or otherwise, provided that such release with respect to employees of Wihlborgs and Medeon shall only apply to any
claims that such individuals have as employees of Wihlborgs or Medeon and not any claims they have as individuals that are not tied to such employment. 

  

	3.9	By signing this Termination Agreement, each of the parties hereto represents and warrants that it has all requisite corporate power and authority to enter into and to
perform its obligations under this Termination Agreement and to consummate the transactions contemplated hereby. This Termination Agreement may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken
together, shall constitute one agreement. This Termination Agreement shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective legal representatives, successors and assigns. 

 

	3.10	This Termination Agreement shall be governed by and construed in accordance with Swedish Law. 

	3.11	Any dispute, controversy or claim arising out of or in connection with this Termination Agreement, or the breach, termination or invalidity hereof, shall be finally
settled by arbitration in accordance with the Rules for Expedited Arbitrations of the Arbitration Institute of the Stockholm Chamber of Commerce. The seat of arbitration shall be Malmö. The language to be used in the arbitral proceedings shall
be Swedish. 

  
  

[Signature Page Follows] 

 This Termination Agreement has been executed as of the Effective Date in four originals, of which the
Parties each has received one. 
  

					
	MEDEON FASTIGHETER AB	 	 	 	ACADIA PHARMACEUTICALS INC.
			
	 /s/ ANDERS JARL
	 		 	 /s/ ULI HACKSELL

	 ANDERS JARL
	 		 	ULI HACKSELL
		 		 	CHIEF EXECUTIVE OFFICER
			
	 WIHLBORGS FASTIGHETER AB (PUBL)
	 		 	NORDSVITEN AB
			
	 /s/ ANDERS JARL
	 		 	 /s/ CHRISTIAN ZÄTTERSTRÖM

	 ANDERS JARL
	 		 	 CHRISTIAN ZÄTTERSTRÖM
 (BY PROXY)

	 /s/ CHRISTER JOHANSSON
	 		 	
	 CHRISTER JOHANSSON

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]